Clinical Trials
- Digestive System
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
- Ages12 years - 75 years
- GenderBoth
- Digestive System
test
- Ages18 years - 75 years
- GenderBoth
- Digestive System
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE)
- Ages60 years - 84 years
- GenderBoth
- Digestive System
test
- Ages40 years and older
- GenderBoth
- Digestive System
test
- Ages18 years - 75 years
- GenderBoth
- Colorectal Cancer, Breast Cancer, Gynecological Cancers, Stomach and Esophagus, Lymphoma, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Melanoma, Thyroid and Other Endocrine Cancers, Other Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Phase 1 Cancers, Cancer
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
- Phase 1 Cancers
test
- Immune System, Men's Health, Women's Health
Effects of circadian regulation and sleep on immune responses
- Ages21 years and older
- GenderBoth
- Phase 1 Cancers
test
- Immune System
Inhibition of Sterile Inflammation by Digoxin
- Ages18 years - 70 years
- GenderBoth